Aktienanalyse zu Personalis Inc (PSNL)PSNLPersonalis Inc

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Currently, Personalis Inc (PSNL) is not a strong buy due to its low RSI of 24.948, indicating oversold conditions, and a recent price of $15.65, which is below the analyst price target of $16.25. The stock has shown a year-to-date change of +99.36%, but the recent 5-day change is -2.19%, suggesting short-term weakness. The main risk is the negative net income of -30,032,000 USD reported for Q1 2026, which raises concerns about profitability.